Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease

Isosorbide dinitrate is one of the most commonly prescribed medications for the treatment of ischemic heart disease. It has been demonstrated to be ineffective relative to placebo when taken inappropriately. This study objectively documents the magnitude and nature of compliance in 68 ambulatory patients who were prescribed isosorbide dinitrate three times a day. Each patient received a 9-week supply of medication in a vial equipped with a computerized monitor (MEMS-4 cap; APREX Corporation, Fremont, CA) and were informed as to the purpose of the study. Of the patients, 74% were classified into the low and 16% into the high compliance category, defined as compliant < 70% and > or = 85% of study days, respectively. The mean (+/- SD) percent days in which isosorbide dinitrate was taken three times was 66% (+/- 29), and the mean number of days in which it was taken three times with a 10-hour "nitrate free period" was 53% (+/- 31). It is concluded that the magnitude of noncompliance in patients prescribed isosorbide dinitrate three times daily is substantial (74%). The nature of this noncompliance is often due to failure to observe a 10- to 12-hour nitrate free period. Given the need to take isosorbide dinitrate appropriately and given the demonstrated magnitude of noncompliance, physicians should take these factors into consideration when selecting this agent for the management of coronary artery disease relative to other pharmacologic options.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. W. R. Cheng, K.-s. Woo, J. C. N. Chan, B. Tomlinson, and J. H. S. You Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device Am. J. Health Syst. Pharm., February 15, 2005; 62(4): 411 - 415. [Full Text] [PDF]

				J. A. Cramer and R. Rosenheck Compliance With Medication Regimens for Mental and Physical Disorders Psychiatr Serv, February 1, 1998; 49(2): 196 - 201. [Abstract] [Full Text]